[Efficacy of Triatec in monotherapy and in combination with Lasilix in a French multicenter study].
The 770 subjects enrolled into the French multicenter trial of Triatec (ramipril) presented the usual characteristics of moderate hypertension. After a low rate of response to placebo (9.1 p. 100), over half the active treatment patients responded to Triatec 2.5 mg (57 p. 100). Later on, Triatec 5 mg achieved control of half the remaining patients (55.6 p. 100); lastly, among non-responders to that posology, no difference was noted between monotherapy with 10 mg of Triatec, and the combination of 20 mg of Lasilix (furosemide) and Triatec 5 mg (respectively 44.7 p. 100 and 47.4 p. 10 responders). As a whole, more than 90 p. 100 of the patients responded to the proposed treatment plan.
Guyot
D
D
Service biométrie, Laboratoires Hoechst, Puteaux.
Lemarié
J C
JC
D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001643:Bridged Bicyclo Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D001952:Bridged-Ring Compounds / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005665:Furosemide / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D017257:Ramipril
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001643:Bridged Bicyclo Compounds; D001952:Bridged-Ring Compounds; D005665:Furosemide; D017257:Ramipril
Efficacité du Triatec en monothérapie et en association au Lasilix dans l'étude multicentrique française.